Cryopreserved Hematopoietic Progentor Cell Products (HPC)

The purpose of the survey is to recognize potential gaps and opportunities for improvement in developing stability programs for cryopreserved hematopoietic progenitor cell (HPC) products.

Well-designed stability programs can:

• Provide evidence of how the quality of a product changes over time
• Establish an expiration date
• Define acceptable storage conditions
• Assess the suitability of container material and closure systems

The following survey will focus on cryopreserved hematopoietic progenitor cell (HPC) products, specifically HPC, Apheresis (HPC-A), HPC, Marrow (HPC-M) and HPC, Cord Blood (HPC-CB). Your participation is critical to our success as we develop a roadmap designed for all members!

Roadmap: Define Product -> Define Testing -> Define Testing Intervals

The survey should take approximately 10-15 minutes for completion.

To avoid duplicate responses, we request that each institution complete the survey only once.

About the AABB-ISCT Joint Working Group:
The WG was formed in January 2015 as a collaborative effort to identify and facilitate projects of common interest to both organizations and their significant overlap of members. In 2019 this group launched a Stability Committee project team which has been tasked with providing recommendations for the establishment of a cellular therapy stability program.
This link has been sent by AABB.

Question Title

* 1. Do you have a stability program in place?

Question Title

* 2. Do you have constraints which limit the implementation of your stability program? (Check all that apply)

Question Title

* 3. Which regulatory requirements are relevant to your stability program? (Check all that apply)

Question Title

* 4. What HPC products are included in your stability program? (check all that apply)

 
7% of survey complete.

T